Filing Flows › Maze Therapeutics (MAZE) › Q1 2026
Maze Therapeutics (MAZE) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 12, 2026
Maze Therapeutics (MAZE) reported revenue of $20.0M for the first quarter 2026 (Q1 2026). Operating margin was -132.8%, net loss $24.2M (121.0% of revenue).
Maze Therapeutics, Q1 2026: revenue $20.0M, operating margin -132.8%, net loss $24.2M, operating cash flow −$39.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $20.0M | — | — |
| Operating profit | −$26.6M | — | — |
| Net earnings | −$24.2M | — | — |
| Operating cash flow | −$39.1M | — | — |
What changed
Revenue was $20.0M in Q1 2026.
Operating costs exceeded revenue by $26.6M, an operating margin of -132.8%. The quarter ended with a net loss of $24.2M.
Operating cash flow was −$39.1M. Non-cash charges added back $444K of depreciation and $7.1M of share-based compensation. Working capital and other items used $22.5M. Capital expenditures of $93K exceeded it, leaving free cash flow of −$39.2M.
Questions
What was Maze Therapeutics' revenue in the first quarter 2026?
Maze Therapeutics (MAZE) reported revenue of $20.0M for the first quarter 2026 (Q1 2026).
Was Maze Therapeutics profitable in the first quarter 2026?
Operating loss was $26.6M (-132.8% of revenue) and net loss $24.2M.
Source: Maze Therapeutics 10-Q on SEC EDGAR.